IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.224
EU - Europa 3.080
AS - Asia 1.587
SA - Sud America 281
AF - Africa 14
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.195
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.051
RU - Federazione Russa 1.368
SG - Singapore 984
IT - Italia 803
BR - Brasile 254
CN - Cina 229
DE - Germania 206
GB - Regno Unito 187
HK - Hong Kong 179
CA - Canada 157
IE - Irlanda 128
FI - Finlandia 109
UA - Ucraina 54
FR - Francia 53
VN - Vietnam 37
NL - Olanda 35
IN - India 33
TR - Turchia 33
AT - Austria 30
SE - Svezia 30
PK - Pakistan 22
AE - Emirati Arabi Uniti 17
ES - Italia 16
BD - Bangladesh 13
RO - Romania 13
AR - Argentina 11
ID - Indonesia 9
MX - Messico 9
PL - Polonia 9
BE - Belgio 8
LT - Lituania 8
MC - Monaco 8
MA - Marocco 6
AU - Australia 5
CZ - Repubblica Ceca 5
JP - Giappone 5
UZ - Uzbekistan 5
CO - Colombia 4
PE - Perù 4
EC - Ecuador 3
HU - Ungheria 3
IQ - Iraq 3
IR - Iran 3
VE - Venezuela 3
AM - Armenia 2
CH - Svizzera 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
IL - Israele 2
MG - Madagascar 2
MY - Malesia 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
ZA - Sudafrica 2
AZ - Azerbaigian 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CL - Cile 1
DZ - Algeria 1
EG - Egitto 1
EU - Europa 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LV - Lettonia 1
PW - Palau 1
PY - Paraguay 1
RS - Serbia 1
SA - Arabia Saudita 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 10.195
Salva come PNG Salva come JPEG
Città #
Chicago 818
Singapore 592
Los Angeles 395
Salt Lake City 386
Buffalo 204
Tampa 200
Chandler 181
Hong Kong 170
Elk Grove Village 159
Beijing 142
Moscow 134
Dublin 128
Wilmington 111
Ashburn 104
Boardman 104
The Dalles 104
Beauharnois 89
Fairfield 84
San Mateo 82
Pisa 79
Sterling 77
Dallas 76
Milan 73
Lancaster 72
Rome 66
Cambridge 61
Munich 61
Florence 57
Seattle 52
Helsinki 49
Dulles 48
Miami 48
Ottawa 41
Portsmouth 40
New York 39
Stevenage 38
Santa Clara 37
Southend 33
Falls Church 32
Detroit 30
Kansas City 30
Lawrence 30
Woodbridge 30
Frankfurt am Main 29
Houston 29
Istanbul 28
Lappeenranta 28
London 28
Nuremberg 28
Turku 27
Jacksonville 25
Washington 23
Lucca 22
Bologna 20
Palermo 19
Pittsburgh 19
São Paulo 19
Dong Ket 18
Livorno 17
Phoenix 17
Genoa 15
Ann Arbor 14
Buti 14
San Diego 14
Vienna 14
Brooklyn 13
Padova 13
Redmond 13
Shanghai 13
Toronto 13
Assago 12
Dearborn 11
Fremont 11
Las Vegas 11
Düsseldorf 10
Lauterbourg 10
Turin 10
Belo Horizonte 9
Cascina 9
Islamabad 9
Naples 9
Norwalk 9
Brussels 8
Monaco 8
Montreal 8
San Francisco 8
West Jordan 8
Atlanta 7
Bari 7
Boston 7
Bucharest 7
Central District 7
Guangzhou 7
Mexico City 7
New Delhi 7
Perugia 7
Amsterdam 6
Chennai 6
Rio de Janeiro 6
Zirl 6
Totale 6.165
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.713
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.483
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 465
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 174
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 174
A simple echocardiographic score to rule out cardiac amyloidosis 162
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 136
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 135
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 123
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 116
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 113
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 111
A simple echocardiographic score to rule out cardiac amyloidosis 109
Biomarkers for the diagnosis and management of heart failure 107
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 106
Atrial amyloidosis: mechanisms and clinical manifestations 104
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 103
[Central apneas and cardiovascular diseases] 98
Cardiovascular disease and COVID-19: les liaisons dangereuses 97
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 95
Role of Imaging in Cardiomyopathies 93
Eligibility for vericiguat in a real‐world, contemporary heart failure population 93
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 93
Biomarkers for the diagnosis and management of heart failure: New frontiers 93
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 93
Molecular autopsy of sudden cardiac death in the genomics era 91
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 90
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 89
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 85
Disease features and management of cardiomyopathies in women 84
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 84
Cardiac magnetic resonance in patients with muscular dystrophies 83
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 83
Treatment of cardiac transthyretin amyloidosis: an update 82
Use of biomarkers to diagnose and manage cardiac amyloidosis 82
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 81
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 80
Valvular heart disease in patients with cardiac amyloidosis 79
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 78
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 77
Current and emerging drug targets in heart failure treatment 74
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 73
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 72
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 71
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 70
Coronary Artery Anomalies 69
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 68
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 68
Valve disease in cardiac amyloidosis: an echocardiographic score 65
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 65
Tissue Characterization in Cardiac Amyloidosis 64
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 64
Cardiovascular toxicity from therapies for light chain amyloidosis 64
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 63
Sex differences in transthyretin cardiac amyloidosis 62
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 62
sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff? 61
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 61
Cardiac Amyloidosis: How Its Epidemiology is Changing 60
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 60
The unbearable underreporting of comorbidities in heart failure clinical trials 60
Safety and Efficacy of Amiodarone in a Patient With COVID-19 60
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 59
RNA-targeting and gene editing therapies for transthyretin amyloidosis 58
Critical Reading of cardiovascular trials with neutral or negative results 57
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 57
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 57
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 57
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 56
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 55
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 54
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 54
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 54
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 53
Pathophysiology of Cardiac Amyloidosis 51
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 51
Obstructive sleep apnea and cardiovascular diseases 50
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 49
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 49
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article ‘Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial’ 46
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 44
Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry 44
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 44
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 42
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 42
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 38
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 37
Statin therapy in COVID-19 infection 35
Targeting precipitants to prevent heart failure hospitalization. Does season matter? 31
Cardiac amyloidosis: Innovations in diagnosis and treatment 21
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 21
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 18
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 16
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 14
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 11
Totale 10.298
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.457
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.457
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202014 0 0 0 0 0 0 0 0 0 0 0 14
2020/2021344 26 28 17 27 13 26 22 24 39 24 49 49
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20257.979 51 97 231 132 304 256 611 1.146 434 1.070 2.215 1.432
Totale 10.298